Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial

by Fumihiko Sakai, Akichika Ozeki, Vladimir Skljarevski
Published 2020-07-01

Predictors of premature discontinuation of treatment in multiple disease states

by Eric Nantz, Hong Liu-Seifert, Vladimir Skljarevski
Published 2009-01-01

Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine...

by Russell Nichols, Vladimir Skljarevski, Grazia Dell’Agnello, Hans-Peter Hundemer, Sheena K. Aurora
Published 2019-03-01

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine

by Michael Ament, Kathleen Day, Virginia L Stauffer, Vladimir Skljarevski, Mallikarjuna Rettiganti, Eric Pearlman, Sheena K. Aurora
Published 2021-02-01

Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine

by Michael Ament, Kathleen Day, Virginia L. Stauffer, Vladimir Skljarevski, Mallikarjuna Rettiganti, Eric Pearlman, Sheena K. Aurora
Published 2021-08-01

Maintenance of effect of duloxetine in Chinese patients with pain due to osteoarthritis: 13-week open-label extension data

by Guochun Wang, Liqi Bi, Xiangpei Li, Zhijun Li, Dongbao Zhao, Jinwei Chen, Dongyi He, Chia-Ning Wang, Tao Wu, Héctor Dueñas, Vladimir Skljarevski, Li Yue
Published 2019-04-01